Mechanism of enhanced oral absorption of hydrophilic drug incorporated in hydrophobic nanoparticles

Liang-Zhong Lv1
Chen-Qi Tong1
Jia Yu1
Min Han2
Jian-Qing Gao2

1Department of Pharmacy, Zhejiang Provincial People’s Hospital, Hangzhou, People’s Republic of China; 2Institute of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People’s Republic of China

Abstract: Hydroxysafflor yellow A (HSYA) is an effective ingredient of the Chinese herb Carthamus tinctorius L, which has high water solubility and low oral bioavailability. This research aims to develop a hydrophobic nanoparticle that can enhance the oral absorption of HSYA. Transmission electron microscopy and freeze-fracture replication transmission electron microscopy showed that the HSYA nanoparticles have an irregular shape and a narrow size distribution. Zonula occludens 1 protein (ZO–1) labeling showed that the nanoparticles with different dilutions produced an opening in the tight junctions of Caco-2 cells without inducing cytotoxicity to the cells. Both enhanced uptake in Caco-2 cells monolayer and increased bioavailability in rats for HSYA nanoparticles indicated that the formulation could improve bioavailability of HSYA significantly after oral administration both in vitro and in vivo.

Keywords: hydroxysafflor yellow A, nanoparticles, Caco-2 cells, bioavailability, absorption

Introduction

Improving the high water solubility and low intestinal permeability of Biopharmaceutics Classification System (BCS) Class III drugs has been a focus of study in pharmaceutical research. Generally, BCS Class III drugs are not adapted to oral formulations. Thus, the addition of an absorption enhancer1 and chemical modification2 is necessary to improve the means of drug delivery3,4 and enhance drug bioavailability (BA), respectively. The flower of the safflower plant, Carthamus tinctorius L, has been widely used in traditional Chinese medicine for treatment of cerebrovascular and cardiovascular diseases.1 Hydroxysafflor yellow A (HSYA) is extracted from the flower of the safflower plant. As the main active component extracted from the safflower plant, it has been demonstrated to have a strong antagonistic effect on the platelet-activating factor receptor5 as well as outstanding neuroprotective action in vivo and in vitro.6 According to recent studies, HSYA is a BCS Class III1,7 hydrophilic drug with low oral bioavailability, which means that it is only administered in clinical therapy via injections.8,9

In this study, hydrophobic nanoparticle oil solutions were prepared to increase the oral absorption of HSYA. Hydrophobic nanoparticle oil solutions are composed of caprylic/capric triglyceride (GTCC), bean phospholipids, and organic solvents. The nanoparticle oil solutions were formed after the organic solvents were volatilized. Through these procedures, small-sized nanoparticles in a stable, oily environment were prepared, and a formulation that is more stable than emulsions was obtained.
This study investigated the possible enhancing mechanism of hydrophobic nanoparticles to HSYA.

**Material and methods**

**Material**

HSYA (98% purity) was purchased from Chengdu Herb purity Company, Ltd (Chengdu, People’s Republic of China), while GTCC (caprylic/capric triglyceride) was obtained from Gattefosse (Saint-Priest, France). Bean phospholipids (Lipoid S 100) were purchased from Lipoid (Ludwigshafen, Germany), and Sephadex G-100 was supplied by the Beijing Investor Science and Technology Development Company, Ltd (Beijing, People’s Republic of China). Methyl-β-cyclodextrin was obtained from the Shanghai Ding Jie Biological Technology Company, Ltd (Shanghai, People’s Republic of China). NaN3, amiloride, rhodamine-123, N-acetyl-L-cysteine, polyoxyethylene (10) octylphenyl ether (Triton X-100) and 3-(4,5-dimethylthiazol -2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St Louis, MO, USA). The rabbit anti-ZO-1 antibody was purchased from Abcam (Cambridge, UK), while the FITC-labeled goat anti-rabbit IgG antibody was purchased from Wuhan Boster Biological Engineering Company, Ltd (Wuhan, People’s Republic of China). Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were purchased from Thermo-Fisher Biochemical Products (Beijing, People’s Republic of China).

**Animals**

Male Sprague-Dawley rats (200 g ± 20 g) were obtained from the Animal Center of Zhejiang University (Hangzhou, People’s Republic of China). The animal experiment was approved by the Animal Ethics Committee of Zhejiang University. The animals were housed in a normal laboratory environment with access to food and water.

**Preparation of HSYA-loaded nanoparticles**

Initially, 500 mg of soybean phospholipids were dissolved in 2 mL methanol. Then, 50 mg of HSYA was added and ultrasonicated to obtain a clarified mixed solution (A). Afterwards, another 500 mg of soybean phospholipids were dissolved in 0.5 mL ethanol and ultrasonicated, then 10 mL GTCC was added to obtain a mixture (B). The A and B mixtures were mixed and homogenized at 9,500 rpm for 2 minutes (FJ-200 High-Speed Dispersion Homogenizer; Jiangsu Jintan Jincheng Instruments Co, Jiangsu, People’s Republic of China) until a clear and transparent formulation was obtained. The organic solvents were removed by using a rotary evaporator (Shanghaijiapeng Technology Company Ltd, Shanghai, People’s Republic of China) for 30 minutes at 40°C.

**Characterization of HSYA-loaded nanoparticles**

**Droplet size and morphology observation**

The newly prepared nanoparticles were filtered through a 0.22 μm organic membrane, and the droplet size was measured by using dynamic light scattering (Nano-S 90; Malvern, Worcestershire, UK). The morphology of the nanoparticle was observed through transmission electron microscopy (TEM) (Philips Tecnai 10; Philips, Amsterdam, Netherlands). The particle size, particle size distribution, and aggregation state of the nanoparticles were characterized by freeze-etching (BAF 060; Leica, Germany) replication TEM (FETEM).

**Encapsulation efficiency, drug loading capacity, and in vitro drug release**

The encapsulation efficiency (EE%) and drug loading capacity (LC%) were determined by using the Sephadex column method, and calculated using the formulas below.\(^{11}\)

\[
EE\% = \frac{\text{HSYA in nanoparticles}}{\text{Total amount of HSYA in dispersion}} \times 100\% \quad (1)
\]

\[
LC\% = \frac{\text{HSYA in nanoparticles}}{\text{Nanoparticles weight}} \times 100\% \quad (2)
\]

Briefly, 20 μL nanoparticles were dissolved in 180 μL methanol to release HSYA as the total amount of HSYA. Another 20 μL nanoparticles was mixed with water (1:4) to form emulsions, then passed through a Sephadex column. The eluted emulsions from the column were further treated by methanol to release HSYA as the content of HSYA in nanoparticles.

In vitro drug release was performed by using the dialysis bag method.\(^{12,13}\) The dialysis bag allowed the transfer of the released drug molecules into the release media while intercepting the nanoparticles. The dialysis bag (molecular weight range: 8,000 to 14,000; Sigma-Aldrich) was boiled for more than 30 minutes and soaked in the release media overnight prior to the experiment; the release media was double-distilled water. One end of the dialysis bag was tied tightly, and 10 mL release media was placed in the bag.
The other end of the dialysis bag was closed with a dialysis clip, and the dialysis bag was then placed in a beaker that contained 200 mL release media. The beaker was placed on a magnetic stirrer (Hangzhou Instrument Electric Co, Ltd) at a rotational speed of 100 rpm at 4°C. Afterwards, 1 mL of the freshly prepared HSY A nanoparticles (3.88 mg/mL) was added to the release media outside the dialysis bag. At the preset time points (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, and 192 hours), 1 mL of the release sample was withdrawn from the media in the dialysis bag, and equal amounts of fresh release media was immediately added into the dialysis bag to maintain the sink condition. The in vitro release of the HSY A solution was carried out by adding the drug solution to the release media and withdrawing the release sample from the release media in the beaker directly and not from the dialysis bag. All samples were analyzed by high-performance liquid chromatography (HPLC).

Caco-2 cell culture

The Caco-2 cells were cultured in a cell incubator with an atmosphere of 5% CO₂ at 37°C. The culture medium was DMEM, which contained 4,500 mg/L D-glucose, 584 mg/L L-glutamine, 3.7 g/L NaHCO₃, supplemented with 10% (volume [v]/v) heat-inactivated FBS, 1% (v/v) penicillin, and 1% (v/v) streptomycin. The culture medium was replaced every 3 to 4 days. Cell subculturing was performed when the cells reached 80% to 90% coverage.

Cell viability assay

Caco-2 cells were seeded in 96-well plates at a density of 10,000 cells/well and cultured for 24 hours with DMEM culture medium. When the experiment was started, the medium was replaced with 200 µL serial dilutions of blank nanoparticles or the control (culture medium). The cells were exposed to the nanoparticles for 2 hours at 37°C, after which 20 µL of MTT reagent (5 mg/mL) in Phosphate Buffer Solution (PBS) was added to each well, and the mixtures were incubated for 4 hours. Then, 180 µL Dimethyl sulfoxide (DMSO) was added to each well, and the mixture was agitated gently to dissolve the crystals completely. The absorbance values were detected by using a KHB ST-360 microplate reader (KHB, Shanghai, People’s Republic of China) at 570 nm. Cell viability was calculated as follows:

Cell viability (%) = \frac{A_{\text{test}}}{A_{\text{control}}} \times 100\% \quad (3)

Transepithelial electrical resistance measurement in Caco-2 cells

Cells were seeded at a density of 2.5 × 10⁵ cells/well in a 12-well polycarbonate membrane transwell (12 mm, 1 µm pore size, 0.3 cm² growth area) obtained from Costar (Silicon Valley, USA). The cells were cultured for 21 days under the previously described culture conditions. The volumes of the culture medium were 0.5 mL and 1.5 mL on the apical and basolateral side, respectively. At 21 days, the cell transepithelial electrical resistance (TEER) was measured using Millicell ERS-2 Volt-Ohm Meter (Millipore, Massachusetts, USA) to evaluate cellular integrity, as previously reported. To evaluate the impact of HSY A solutions, HSY A-nanoparticles and blank nanoparticles on cells integrity, 3.88 mg/mL of HSY A solutions and the same concentration of HSY A-nanoparticles and blank nanoparticles were all diluted 10-fold to incubate with Caco-2 cells for 2 hours. The TEER was also measured when the formulation was removed after 2 hours of incubation, and the culture was continued up to 24 hours and 48 hours to evaluate if the impact of the formulation on cell integrity was reversible.

Cellular uptake of HSYA

Cells were seeded at a density of 2.5 × 10⁵ cells/well onto six-well plates and cultured for 14 days for the uptake experiments. Cells were treated with different concentrations of HSY A solution and HSY A nanoparticles for 2 hours. The cells were preincubated with a number of endocytotic inhibitors, such as NaN₃ (1.32 mg/mL), chlorpromazine (10 µg/mL), methyl-β-cyclodextrin (methyl-β-CD) (13.3 mg/mL), and amiloride (50 µM), for 30 minutes to understand the endocytotic mechanism of the formulations. Blank nanoparticles were also added to investigate whether they have an effect on Caco-2 cellular uptake of HSY A. At the end of the experiments, the cells were washed three times using ice-cold PBS, then frozen and thawed three times. One mL of water was added to each well. The wells were probe-sonicated 25 times to obtain the cell lysates. The lysates were centrifuged at 13,000 rpm for 5 minutes, and the supernatant liquid was analyzed using HPLC.

Cellular transport of HSYA

Caco-2 cells were seeded onto the 12-well transwell at a density of 2.5 × 10⁵ cells/well and cultured at a condition similar to that during TEER measurements. At 21 days, the transmembrane resistance met the requirements, and the cell model was ready for transport experiments. One mg/mL
of the HSYA solutions was added to the apical side of the cells, and 1.5 mL DMEM without FBS was added to the basolateral side. At 15, 30, 45, 60, 90, 120, 180, 240, 360, and 480 minutes, 500 µL of the sample from the basolateral side was collected and replaced with the same volume of fresh DMEM without FBS. Another group of cells was preincubated with 150 µg/mL of cyclosporin A (CsA, a recognized p-glycoprotein [p-gp]) for 30 minutes. The cells were preincubated with 0.5 mL methanol, added to the samples of the nanoparticle group, and then probe-sonicated 25 times (4°C, 150 W, active every 2 seconds within a 3-second duration). All samples were centrifuged at 13,000 rpm for 5 minutes. Then, 50 µL of the supernatant was injected into the liquid chromatography system (Agilent 1,200 system; Agilent, Santa Clara, CA, USA) for investigation.

**Effect of HSYA nanoparticles on ZO-1 distribution**

The cells were seeded in a 12-well polycarbonate membrane transwell at a density of 2.5×10^5 cells/well and cultured for 21 days before the experiment, followed by incubation with 10-fold dilution HSYA nanoparticles for 2 hours at 37°C. Then, the cells were washed three times with ice-cold PBS and fixed with 4% paraformaldehyde solution for 30 minutes, followed by rinsing with ice-cold PBS two times and permeabilization in 0.2% Triton X-100/PBS for 5 minutes. Non-specific binding was blocked with 5% Bovine serum albumin (BSA)/PBS for 30 minutes. Primary antibody (rabbit anti-ZO-1 antibody) at a concentration of 1:100 was applied and incubated at room temperature for 2 hours. The cells were washed three times with PBS, and the secondary antibody (FITC-conjugated goat anti-rabbit IgG) was added at a concentration of 1:48 and incubated at room temperature for 1 hour. Finally, the cells were washed three times with PBS and observed under two-photon confocal microscopy (BX61 W1-FV1000; Olympus, Japan).

**In vivo pharmacokinetic studies**

Pharmacokinetic studies were carried out by dividing the rats into two groups, with three rats in each group. The animals in the HSYA group were given a dose of 25 mg/kg, which was also the dose given in our previous study.11 Another group received the oral HSYA nanoparticles at a dose of 25 mg/kg. After the administration of HSYA solution and HSYA formulations to the rats through oral gavage, blood samples were collected from the eye ground vein into heparinized tubes at preset time points of 5, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1,440 minutes. The blood samples were centrifuged at 4,000 rpm for 10 minutes, and the supernatant was transferred into another plastic tube and stored at −20°C until further analysis.

**Determination of HSYA concentrations in plasma**

The plasma concentrations of HSYA were determined through HPLC, as we described in our preliminary work.11 Two hundred ul plasma samples were collected in plastic centrifuge tubes with 100 µL of 6% perchloric acid added to precipitate protein. The mixture was vortexed for 2 minutes. After centrifugation at 13,000 rpm for 10 minutes, the supernatant was detected using HPLC.

**HPLC analysis of samples**

Chromatographic conditions were performed according to the literature:13 a C18 column (Agilent SRB-C18, 5µm, 4.6 mm × 250 mm, Agilent) was used at 40°C. The mobile phase was 32% methanol, 2% acetonitrile, and 66% phosphate solution (0.1% concentration). The injection volume was 50 µL, and the flow rate was 0.8 mL/minute. The detection signal was 403 nm.

**Pharmacokinetic analysis**

The maximum plasma concentration was defined as \( C_{\text{max}} \), while the time to reach \( C_{\text{max}} \) was defined as \( t_{\text{max}} \). The area under the plasma concentration-time curve (AUC) and mean retention time (MRT) were calculated from 0 hours to 12 hours. All parameters were calculated by using Kinetica 4.4 software (Thermo Fisher Scientific Inc., MA, USA).

**Statistical analysis**

All values are expressed as mean ± standard deviation (SD). Statistical significance was assessed using one-way analysis of variance (ANOVA) among more than three groups, with \( P<0.05 \) considered statistically significant. The means of the two groups were compared by performing two-tailed student's \( t \)-tests.

**Results**

**Characterization of HSYA-loaded nanoparticles**

Figure 1A and B show that the freshly prepared HSYA nanoparticles were diluted with 10-fold GTCC. The morphology of the diluted nanoparticles was characterized by TEM and FERTEM. Figure 1A shows that the formed nanoparticles exhibited a spherical structure with a relatively uniform size. FERTEM was performed to further characterize the
nanoparticles, and to evaluate the impact of nanostructures on drug release. In the case of the HSY A solution, complete release was obtained after 0.5 hours, whereas in the case of the HSY A nanoparticles, HSY A was totally released from the nanoparticles after 192 hours (approximately 50% was totally released), and the release was better sustained in vitro.

**Cell viability assay**
Figure 3A shows that the blank nanoparticles diluted 10-, 15-, 30-, and 50-fold showed almost no cytotoxicity after incubation for 2 hours.

**TEER measurement in Caco-2 cells**
Figure 3B shows that after the 2-hour incubation of HSY A solution and HSY A nanoparticles, the TEER of Caco-2 cells decreased. The TEER did not significantly increase after the HSY A solution or the HSY A-loaded nanoparticles were removed and culture continued for 24 hours and 48 hours. When the blank nanoparticles were incubated for 2 hours, the TEER did not decrease. The TEER increased with continued cell culture. From these results, we hypothesize that HSY A is somewhat toxic to Caco-2 cells, thereby destroying the integrity of the cells. The blank nanoparticles showed almost no effect on the integrity of the cells.

**Cellular uptake and transport studies of HSYA**
Figure 4B shows that the apparent permeability coefficient (Papp) of 1 mg/mL HSY A was $(5.38 \pm 1.58) \times 10^{-7}$, which...
increased to \((1.27 \pm 0.64) \times 10^{-6}\) when the Caco-2 cells were preincubated with CsA (p-glycoprotein inhibitors) for 30 minutes. This result indicates the presence of p-glycoprotein efflux, which may be one of the reasons behind poor HSYA absorption. Figure 4A shows that both high and low concentrations of HSYA nanoparticles can significantly promote HSYA absorption.

Endocytotic inhibitor experiments were conducted (Figure 4C) to clarify how the nanoparticles promote HSYA absorption. Prior to the experiments, Caco-2 cells were preincubated for 30 minutes with three kinds of inhibitors, namely, chlorpromazine (10 µg/mL) to inhibit clathrin vesicles, methyl-β-CD (13.3 mg/mL) to inhibit caveolae, and amiloride (50 µM) to inhibit pinocytosis. However, the results revealed that the inhibitors did not have any significant effect on HSYA uptake. Blank nanoparticles also have no significant effect on HSYA absorption.

**Effect of HSYA-loaded nanoparticles on ZO-1 distribution**

ZO-1 is a tight junction-associated protein that is localized on the cytoplasmic surface just beneath the membrane. Figure 5A shows that the ZO-1 of the control group was uniformly distributed in the tight connection region of the cell. However, in comparison to the control cell layers, the individual regions exhibited discontinuous distribution in the HSYA nanoparticle group, and part of the cells exhibited extrusion and deformation.

**In vivo pharmacokinetic studies**

The plasma concentration-time profiles of HSYA after intravenous or oral administration of HSYA solution and HSYA nanoparticles to rats are shown in Figure 6, and the pharmacokinetic parameters are summarized in Table 1. The AUC of HSYA nanoparticles was 23.3-fold greater than that of the HSYA solution.

**Discussion**

HSYA is the main component of safflower yellow pigments, which is the aqueous extract of safflower florets. Recent studies investigated the effect of HSYA on lipopolysaccharide-induced inflammatory signal transduction in human alveolar epithelial A549 cells, which includes inhibition of protein oxidation/nitration, 12/15-lipoxygenase, exertion of therapeutic actives on cerebral ischemia induced by thrombosis, and promotion of blood circulation by influencing hemorheology, plasma coagulation, and platelet aggregation, among others. HSYA is a hydrophilic drug with poor oral bioavail-

---

**Figure 4**

(A) HSYA solution and HSYA nanoparticle uptake by Caco-2 monolayers after incubation for 2 hours; (B) HSYA transport across Caco-2 cells (surface area of monolayer = 1.12 cm²); (C) Endocytotic inhibitor studies on Caco-2 cells of HSYA-NPs.

**Notes:** *P<0.05; **P<0.01, compared to control.

**Abbreviations:** CSA, cyclosporin A; HSYA, hydroxysafflor yellow A; Methyl-β-CD, methyl-β-cyclodextrin; NP, nanoparticle; T, time.
ability,\textsuperscript{1,10} which limits its application in clinical practice despite its many prominent pharmacological effects. In our previous studies,\textsuperscript{11} we developed a self-double-emulsifying drug delivery system (SDEDDS), which was composed of water in oil emulsions and hydrophilic surfactants that can self-emulsify into water-in-oil-in-water (w/o/w) double emulsions in the aqueous gastrointestinal environment. This formulation increased the oral bioavailability of HSY\textsubscript{A} 2.17-fold compared to HSY\textsubscript{A} solution.

In this study, we developed a hydrophobic nanoparticle oil solution, the novel formulation of which could be a nanocarrier for hydrophilic drugs with the drug dispersed in the oil phase. Actually, a clear and transparent nanoparticle oil solution was formed when organic solutions A and B were mixed, which means HSY\textsubscript{A} could be dissolved in organic solvent with soybean phospholipids. After the evaporation of organic solvent, the nanoparticles of HSY\textsubscript{A}/soybean phospholipids dispersed in GTCC were formed with the structure of a hydrophilic core and hydrophobic surface. As a water soluble drug, HSY\textsubscript{A} was wrapped in the core of nanoparticles. No deposition could be observed. The formulation composition and preparation process in the present study was determined after some experimental optimization, as not all kinds of oil and surfactant could form the nanoparticles of “hydrophilic drug dispersed in hydrophobic oil”. Due to its pure anhydrous environment, the nanoparticle was more stable for HSY\textsubscript{A} when compared to SDEDDS. From the pharmacokinetic results (Figure 6 and Table 1), we can see that the nanoparticles increased the absolute bioavailability and relative bioavailability to 23.6- and 23.3-fold, respectively. Figure 1 shows that the nanoparticles exhibited an irregular structure, with a particle size of 49.2 nm ± 5.8 nm. The polydispersity of HSY\textsubscript{A} nanoparticles was 0.38, which indicated that the particle size distribution of nanoparticles is relatively non-uniform. In the future, we will optimize the prescription of nanoparticles in order to get uniform size, and to shape rounded particles. In this article, the reversed-dialysis bag method was applied to the in vitro release studies,\textsuperscript{23} and sustained in vitro release was achieved (Figure 2). However, the nanoparticles did not exhibit a sustained release effect in vivo. We speculate

**Table 1** Pharmacokinetic parameters after intravenous or oral administration of HSY\textsubscript{A} formulations to rats

| Parameter                  | Intravenous HSY\textsubscript{A} | Oral HSY solution | HSYA-NPs |
|----------------------------|----------------------------------|-------------------|-----------|
| T\textsubscript{max} (min)  | 5                                | 45 ± 15           | 90.0 ± 51.96 |
| C\textsubscript{max} (µg/mL) | 56.51 ± 29.05                    | 0.33 ± 0.05       | 4.80 ± 2.77† |
| AUC\textsubscript{0−12} (µg minute/mL) | 2,477.68 ± 221.11        | 39.92 ± 6.20      | 931.53 ± 406.34‡‡ |
| MRT (minute)               | 77.47 ± 6.74                    | 227.20 ± 12.29    | 311.12 ± 26.52†† |
| T\textsubscript{max} (minute) | 353.32 ± 64.29                  | 407.61 ± 241.36   | 579.97 ± 216.47   |
| F\textsubscript{rel} (%)    | 100                              | 2.333             | 38          |

Notes: The values represent mean ± standard deviation (n = 3); †P < 0.05 compared to control; ††P < 0.01; ‡‡P < 0.005 compared to control.

Abbreviations: AUC, areas under the concentration time curve; C\textsubscript{max}, maximum plasma concentration; F\textsubscript{rel}, relative bioavailability; F\textsubscript{abs}, absolute bioavailability; HSY\textsubscript{A}, hydroxysafflor yellow A; MRT, mean retention time; NPs, nanoparticles; T\textsubscript{max}, time to maximum plasma concentration.

**Figure 5** (A) ZO-1 staining in control cell layers not subjected to HSY\textsubscript{A} nanoparticles; (B) ZO-1 staining in cells incubated with 10-fold dilution HSYA-NPs for 2 hours at 37°C.

Abbreviations: HSY\textsubscript{A}, hydroxysafflor yellow A; NP, nanoparticle.

**Figure 6** (A) Plasma concentration-time profiles of HSY\textsubscript{A} after intravenous administration of HSY\textsubscript{A} solution, (B) oral administration of HSY\textsubscript{A} solution, and (C) HSY\textsubscript{A}-NPs to rats at a dose of 25 mg/kg.

Abbreviations: HSY\textsubscript{A}, hydroxysafflor yellow A; NP, nanoparticle.
that there are significant differences between in vivo and in vitro environments.

Results of uptake studies on Caco-2 cells (Figure 4A) showed that the formulation can remarkably increase the membrane permeability of HSYA across Caco-2 cell monolayers at low and high concentrations. However, the endocytotic mechanism of nanoparticles is complex. When cells were pretreated with endocytosis inhibitors, such as chlorpromazine, methyl-β-CD, and amiloride, for 30 minutes, the uptake of HSYA decreased to some extent, but did not differ significantly (Figure 4C). Based on the endocytosis results, we assume that the uptake process of HSYA nanoparticles may involve a number of factors. As shown from Figure 4B, CsA (a recognized p-glycoprotein inhibitor) could significantly increase the absorption of HSYA on Caco-2 cells, which indicated that the presence of p-glycoprotein efflux may be involved in HSYA absorption. Although there are no other studies in the literature discussing the mechanisms for the low absorption of HSYA solution, our preliminary studies support this hypothesis. Figure 5 shows that the treatment of a monolayer with HSYA nanoparticles at a 1:10 dilution appeared to cause a redistribution of ZO-1. The results indicate that the formulation could break the tight junction of Caco-2 cell layers to promote drug absorption through the paracellular pathway. Meanwhile, the cells were treated with blank-nanoparticles (NPs) for 2 hours followed by another 48-hour incubation with fresh culture medium without blank-NPs, and cell membrane integrity was not influenced as indicated by the TEER results (Figure 3A), suggesting good biocompatibility of the nanoparticles.

Conclusion

In the present study, a novel oral delivery system of HSYA was developed to improve the oral bioavailability of HSYA. The prepared nanoparticles had a diameter of 49.2 nm ± 5.8 nm and had sustained release properties. The results of Caco-2 monolayer uptake and pharmacokinetics studies suggest increased HSYA absorption both in vitro and in vivo, which indicates great potential for the future formulation of HSYA.

Acknowledgments

This study was funded by the Natural Science Foundation of Zhejiang Province, People’s Republic of China (No Y2100564; No Y2110124; No Y2100645).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Wang S, Sun M, Ping Q. Enhancing effect of Labrafac Lipophile WL 1349 on oral bioavailability of hydroxyasflor yellow A in rats. Int J Pharm. 2008;358(1–2):198–204.
2. Asada H, Douen T, Waki M, et al. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci. 1995;84(6):682–687.
3. Dunn SP, Cooney GF, Kulinsky A, et al. Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. Transplantation. 1995;60(12):1438–1442.
4. Deshmukh DD, Ravis WR, Betageri GV. Improved delivery of cromolyn from oral propolisomal beads. Int J Pharm. 2008;358(1–2):128–136.
5. Zang BX, Jin M, Si N, Zhang Y, Wu W, Piao YZ. [Antagonistic effect of hydroxyasflor yellow A on the platelet activating factor receptor]. Yao Xue Xue Bao. 2002;37(9):696–699. Chinese.
6. Zhu H, Wang Z, Ma C, et al. Neuroprotective effects of hydroxyasflor yellow A in vivo and in vitro studies. Planta Med. 2003;69(5):429–433.
7. Chi D, Liu W, Huang Z, Liu S, Fu X, Liu K. Pharmacokinetics and excretion of hydroxyasflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs. Planta Med. 2006;72(5):418–423.
8. Qin F, Huang X, Guanxin II (II) for the management of coronary heart disease. Chin J Integr Med. 2009;15(6):472–476.
9. Liu SX, Zhang Y, Wang YF, et al. Upregulation of heme oxygenase-1 expression by hydroxyasflor yellow A confirming protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol. 2012;160(2):95–101.
10. Qi J, Zhaung J, Wu W, et al. Enhanced effect and mechanism of water-in-oil microemulsion as an oral delivery system of hydroxyasflor yellow A. Int J Nanomedicine. 2011;6:985–991.
11. Lv LZ, Tong CQ, Lv Q, et al. Enhanced absorption of hydroxyasflor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies. Int J Nanomedicine. 2012;7:4099–4107.
12. Hu W, Dong H, Li YZ, Hu XT, Han GJ, Qu YB. A high-throughput model for screening anti-tumor agents capable of promoting polymerization of tubulin in vitro. Acta Pharmacol Sin. 2004;25(6):775–782.
13. Boukhettala N, Claeyssens S, Bensifi M, et al. Effects of essential amino acids or glutamine deprivation on intestinal permeability and protein synthesis in HCT-8 cells: involvement of GCN2 and mTOR pathways. Amino Acids. 2012;42(1):375–383.
14. Ma TY, Nguyen D, Bui V, Nguyen H, Hoa N. Ethanol modulation of intestinal epithelial tight junction barrier. Am J Physiol. 1999;276(4 Pt 1):G965–G974.
15. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces. 2011;88(1):483–489.
16. Hu K, Cao S, Hu F, Feng J. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. Int J Nanomedicine. 2012;7:3537–3545.
17. Roger E, Kalscheuer S, Kirtane A, et al. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Pharmaceutics. 2012;4(7):2103–2110.
18. Tian Y, Yang ZF, Li Y, et al. Pharmacokinetic comparisons of hydroxyasflor yellow A in normal and blood stasis syndrome rats. J Ethnopharmacol. 2010;129(1):1–4.
19. Song L, Zhu Y, Jin M, Zang B. Hydroxyasflor yellow A inhibits lipopolysaccharide-induced inflammatory signal transduction in human alveolar epithelial A549 cells. Fioptera. 2013;84:107–114.
20. Sun L, Yang L, Xu YW, et al. Neuroprotection of hydroxyasflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res. 2012;1473:227–235.
21. Zhu HB, Zhang L, Wang ZH, et al. Therapeutic effects of hydroxysafflor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms. *J Asian Nat Prod Res*. 2005;7(4):607–613.

22. Liu L, Duan JA, Tang Y, et al. Taoren-Honghua herb pair and its main components promoting blood circulation through influencing on hemorheology, plasma coagulation and platelet aggregation. *J Ethnopharmacol*. 2012;139(2):381–387.

23. Levy MY, Benita S. Drug release from submicronized o/w emulsion – a new in vitro kinetic evaluation model. *Int J Pharm*. 1990;66(1–3):29–37.